These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 25752266)

  • 1. Analysis of repeated low-dose challenge studies.
    Nolen TL; Hudgens MG; Senb PK; Koch GG
    Stat Med; 2015 May; 34(12):1981-92. PubMed ID: 25752266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogates of protection in repeated low-dose challenge experiments.
    Long DM; Hudgens MG; Wu CD
    Stat Med; 2015 May; 34(10):1747-60. PubMed ID: 25628249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of retroviral infection influences anamnestic immune response in vaccinated primates.
    Anderson DE; Singapuri A; Kang KH; Montefiori DC; Torres JV
    Viral Immunol; 2005; 18(4):689-94. PubMed ID: 16359235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS vaccines show promise in primates.
    Clin Infect Dis; 2001 Oct; 33(7):i-ii. PubMed ID: 11592258
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination.
    Velu V; Kannanganat S; Ibegbu C; Chennareddi L; Villinger F; Freeman GJ; Ahmed R; Amara RR
    J Virol; 2007 Jun; 81(11):5819-28. PubMed ID: 17376899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV.
    Kuznetsov VA; Stepanov VS; Berzofsky JA; Belyakov IM
    J Clin Virol; 2004 Dec; 31 Suppl 1():S69-82. PubMed ID: 15567097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
    Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O
    J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges.
    Rasmussen RA; Ong H; Song R; Chenine AL; Ayash-Rashkovsky M; Hu SL; Polacino P; Else JG; Novembre FJ; Ruprecht RM;
    AIDS; 2007 Sep; 21(14):1841-8. PubMed ID: 17721091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.
    Suh YS; Park KS; Sauermann U; Kim KS; Ahn SS; Franz M; Schulte R; Wilfingseder D; Stoiber H; Uberla K; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2008 Dec; 26(51):6690-8. PubMed ID: 18694796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells.
    Yin J; Dai A; Kutzler MA; Shen A; Lecureux J; Lewis MG; Waldmann T; Weiner DB; Boyer JD
    AIDS; 2008 Sep; 22(14):1739-48. PubMed ID: 18753858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose.
    Cranage MP; Sharpe SA; Whatmore AM; Polyanskaya N; Norley S; Cook N; Leech S; Dennis MJ; Hall GA
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1935-44. PubMed ID: 9714241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
    Regoes RR; Longini IM; Feinberg MB; Staprans SI
    PLoS Med; 2005 Aug; 2(8):e249. PubMed ID: 16018721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.